Oak Hill Bio has shared a community letter to the Angelman syndrome community with an important update on the next steps of the development of rugonersen.
They are actively preparing to initiate the Phase 3 study in the middle of 2026. Eligibility criteria are available on clinicaltrials.gov; additional details, including study locations, will be updated as they become available.
On October 8, 2026, ASF and FAST hosted a webinar with Ultragenyx after the announcement that their phase 3 trial for GTX-102 (aspire) did not meet primary or key secondary
Read the press release
Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16
Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.
